New results from a tuberculosis vaccine trial indicate that the Mycobacterium vaccae (MV) was effective in preventing TB among people with HIV. Given that TB is the No. 1 killer of people with HIV in the developing world, this could be a major advance in the battle against these synergistic scourges.
In the seven-year study in Tanzania, researchers with Dartmouth University and other partner institutions found that immunization with MV reduced the rate of TB by 39 percent. Now, they said, the focus needs to turn to manufacturing larger amounts of the vaccine for additional studies and possible clinical use.